Advertisement

Digestive Diseases and Sciences

, Volume 44, Issue 5, pp 939–944 | Cite as

Serum Immunoglobulin and Soluble IL-2 Receptor Levels in Small Intestinal Overgrowth with Indigenous Gut Flora

  • Stephen M. Riordan
  • Christopher J. Mciver
  • Denis Wakefield
  • Mervyn C. Thomas
  • Vic M. Duncombe
  • Terry D. Bolin
Article

Abstract

Murine studies have demonstrated that thepresence of indigenous gut flora is crucial for theinduction of systemic immune hyporesponsiveness toantigens initially encountered within thegastrointestinal lumen. This study investigated whetherincreased titers of such flora, as occur in human smallintestinal bacterial overgrowth, may be associated withincreased suppression of systemic immune responsiveness and the possible relation between systemic andmucosal immunity in this setting. Serum totalimmunoglobulin (Ig), immunoglobulin subclass, andsoluble interleukin-2 receptor levels and lamina propriaIgA plasma cell counts were determined in 50consecutive subjects with (N = 30) and without (N = 20)small intestinal bacterial overgrowth. Luminal IgAlevels were measured in 35 of these subjects. Serumconcentrations of IgG3, but not of otherimmunoglobulin isotypes or soluble interleukin-2receptors, were significantly reduced in subjects withbacterial overgrowth (P < 0.0005). Small intestinallamina propria IgA plasma cell counts (P < 0.0005) andluminal IgA concentrations (P = 0.001) weresignificantly increased in this group. SerumIgG3 levels were significantly inverselycorrelated with luminal IgA levels (P < 0.01) and fell below the lower limit ofnormal (0.41 g/liter) in 17/30 (56.7%) subjects withbacterial overgrowth compared to 1/20 (5.0%) subjectswithout (P < 0.0005). These findings document an association between small intestinalbacterial overgrowth with indigenous gut flora andreduced serum IgG3 reactivity in humans,possibly via an interaction with mucosa-relatedimmunoregulatory mechanisms. The possibility of underlying small intestinalbacterial overgrowth should be considered in patientswith serum IgG3 deficiency, especially thosewith compatible symptoms and/or knownpredisposition.

INDIGENOUS GUT FLORA BACTERIAL OVERGROWTH SYSTEMIC IMMUNITY 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

REFERENCES

  1. 1.
    Weiner HL, Friedman A, Miller A, Khoury SJ, Al-Sabbagh A, Santos L, Sayrgh M, Nussenblatt RB, Trentham DE, Halfer DA: Oral tolerance: Immunologic mechanisms and treatment of animal and human organ-specific autoimmune diseases by oral administration of autoantigens. Annu Rev Immunol 12:809–837, 1994Google Scholar
  2. 2.
    Haeney MR: Immune disorders of the gastrointestinal tract. In DJ Weatherall, JGG Ledingham, DA Warrell (eds). Oxford Textbook of Medicine, 3rd ed. Oxford, Oxford University Press, 1996, pp 1836–1845Google Scholar
  3. 3.
    Melamed D, Friedman A: Direct evidence for anergy in T lymphocytes tolerized by oral administration of ovalbumin. Eur J Immunol 23:935–942, 1993Google Scholar
  4. 4.
    Miller A, Lider O, Roberts AB, Sporn M, Weiner HL: Suppressor T cells generated by oral tolerization to mye lin basic protein suppress both in vitro and in vivo immune responses by the release of TGF-b following antigen-specific triggering. Proc Natl Acad Sci USA 89:421–425, 1992Google Scholar
  5. 5.
    Wannemuehler MJ, Kiyono H, Babb LJ, Michalek SM, McGhee JR: Lipopolysaccharide (LPS) regulation of the immune response: LPS converts germfree mice to sensitivity to oral tolerance induction. J Immunol 129:959–965, 1982Google Scholar
  6. 6.
    Sudo N, Sawamura S, Tanaki K, Aiba Y, Kubo C, Koga Y: The requirement of intestinal bacterialflora for the development of an IgE production system fully susceptible to oral tolerance induction. J Immunol 159:1739–1745, 1997Google Scholar
  7. 7.
    Riordan SM, McIver CJ, Wakefield D, Duncombe VM, Bolin TD, Thomas MC: Luminal immunity in small intestinal bacterial overgrowth and old age. Scand J Gastroenterol 31:1103–1109, 1996Google Scholar
  8. 8.
    Kitani A, Strober W: Regulation of Cg subclass germ-line transcripts in human peripheral blood B cells. J Immunol 151:3478–3488, 1993Google Scholar
  9. 9.
    Fujieda S, Zhang J, Saxon A: IL-4 plus CD40 monoclonal antibody induces human B cells gamma subclass-specificisotype switch: Switching to gamma 1, gamma 3, and gamma 4, but not gamma 2. J Immunol 155:2318–2328, 1995Google Scholar
  10. 10.
    Takatsu K, Tominaga A, Harada N, Mita S, Matsumoto M, Takahashi T, Kikuchi Y, Yamaguchi N: T cell-replacing factor (TRF)/interleukin 5 (IL-5): Molecular and functional properties. Immunol Rev 102:107–135, 1988Google Scholar
  11. 11.
    McGhee JR, Beagley KW, Eldridge JH, Fujihashi K, Lue C, Moldoveanu Z, Mestecky J, Radl J, Kiyono H: Interleukin cascade for the regulation of IgA synthe sis and immune responses. Protides Biol Fluids 36:183–191, 1989Google Scholar
  12. 12.
    Rubin LA, Kurman CC, Fritz ME, Biddison WE, Boutin B, Yarchoan R, Nelson DL: Soluble interleukin 2 receptors are released from activated human lymphoid cells in vitro. J Immunol 135:3172–3177, 1985Google Scholar
  13. 13.
    Felser JM, Raff MJ: Infectious diseases and aging: Immunologic perspectives. JAGS 31:802–807, 1983Google Scholar
  14. 14.
    Thoman ML, Weigle WO: The cellular and subcellular basis of immunosenescence. Adv Immunol 46:221–261, 1989Google Scholar
  15. 15.
    Simon GL, Gorbach SL: The human intestinal microflora. Dig Dis Sci 31( suppl):147–162, 1986Google Scholar
  16. 16.
    Kirsch G: Bacterial overgrowth. Am J Gastroenterol 85:231–237, 1990Google Scholar
  17. 17.
    Haboubi NY, Montgomery RD: Small-bowel bacterial overgrowth in elderly people: Clinical significance and re sponse to treatment. Age Ageing 21:13–19, 1992Google Scholar
  18. 18.
    Cowan ST: Cowan & Steel's Manual for the Identiifcation of edical Bacteria, 2nd ed. Cambridge, Cambridge University Press, 1979Google Scholar
  19. 19.
    Valdovinos MA, Camilleri M, Thamforde GM, Frie C: Reduced accuracy of 14C-D-xylose breath test for detecting bacterial overgrowth in gastrointestinal motility disorders. Scand J Gastroenterol 28:963–968, 1993Google Scholar
  20. 20.
    Riordan SM, McIver CJ, Wakefield D, Duncombe VM, Bolin TD, Thomas MC: Luminal antigliadin antibodies in small intestinal bacterial overgrowth. Am J Gastroenterol 92:1335–1338, 1997Google Scholar
  21. 21.
    Arranz E, O'Mahony S, Barton JR, Ferguson A: Immunosenescence and mucosal immunity: Significant effects of old age on secretory IgA concentrations and intraepithelial lymphocyte counts. Gut 33:882–886, 1992Google Scholar
  22. 22.
    Cockroft DW, Gault MH: Prediction of cre atinine clearance from serum creatinine. Nephron 16:31–41, 1976Google Scholar
  23. 23.
    Rubin LA, Nelson DL: The soluble interleukin-2 receptor: Biology, function and clinical application. Ann Intern Med 113:619–627, 1990Google Scholar
  24. 24.
    Skvaril F: IgG subclasses in viral infections. Monogr Allergy 19:134–143, 1986Google Scholar
  25. 25.
    Richman LK, Graeff AS, Yarchoan R, Strober W: Simultaneous induction of antigen-specfic IgA helper T cells and IgG suppressor T cells in murine Peyer' s patch after protein feeding. J Immunol 126:2079–2083, 1981Google Scholar
  26. 26.
    Cummins AG, Pentilla IA, LaBrooy JT, Robb TA, Davidson GP: Recovery of the small intestine in coeliac disease on a gluten-free diet: Change s in intestinal perme ability, small bowel morphology and T-cell activity. J Gastroenterol Hepatol 6:53–57, 1991Google Scholar
  27. 27.
    Dalekos GN, Manoussakis MN, Goussia AC, Tsianos EV, Moustopoulos HM: Soluble interleukin-2 receptors, antineutrophil cytoplasmic antibodies and other autoantibodies in patients with ulcerative colitis. Gut 34:658–664, 1993Google Scholar
  28. 28.
    Bruggemann M, Williams GT, Bindon CI, Clark MR, Walker MR, Jefferis R, Waldmann H, Neuberger MS: Comparison of the effector functions of human immunoglobulins using a matched set of chimeric antibodies. J Exp Med 166:1351–1361, 1987Google Scholar
  29. 29.
    Oxelius VA, Hanson LA, Bjorkander J, Hammastrom L, Sjoholm A: IgG3 deficiency: Common in obstructive lung disease. Monogr Allergy 20:106–115, 1986Google Scholar
  30. 30.
    . Hammarstrom L, Smith CIE: Critical aspects on diagnosing IgG subclass deficiency and its clinical consequence. Protides Biol Fluids 36:133–138, 1989Google Scholar
  31. 31.
    Jefferis R, Kumararatne DS: Selective IgG subclass deficiency: Quantitation and clinical relevance. Clin Exp Immunol 81:357–367, 1990Google Scholar
  32. 32.
    Snowden JA, Milford-Ward A, Cookson LJ, McKendrick MW: Recurrent lymphocytic meningitis associated with isolated IgG subclass 3 deficiency. J Infect 27:285–289, 1993Google Scholar
  33. 33.
    Snowden JA, Milford-Ward A, Reilly JT: Symptomatic IgG3 deficiency successfully treated with intravenous immunoglobulin therapy. Postgrad Med J 70:924–926, 1994Google Scholar

Copyright information

© Plenum Publishing Corporation 1999

Authors and Affiliations

  • Stephen M. Riordan
  • Christopher J. Mciver
  • Denis Wakefield
  • Mervyn C. Thomas
  • Vic M. Duncombe
  • Terry D. Bolin

There are no affiliations available

Personalised recommendations